"Cold chain requires quality infrastructure"…Temp Chain Company

Hyun Chul Kim, CEO of Temp Chain Company

Achieved significant transportation results amid paradigm shifting…has entered the commercialization stage

A comprehensive technology, including the materials and the system..proven competitiveness

Expanding to ocean freight, moving beyond air…aims to establish bio transportation infrastructure

As the biopharmaceutical market expands, the importance of quality control during the drug transportation phase is growing rapidly.

Temp Chain Company, a company specializing in passive cold chain technology, is accelerating its push into the global market, specifically targeting the large-scale biopharmaceutical transport sector.

By focusing on large-scale shipping containers that maintain temperatures for extended periods without external power, the company is expanding collaborations with global pharmaceutical giants and logistics firms. The company is also pursuing a strategy to extend its reach from air-centric transport to ocean freight, aiming to establish itself as a core bio-logistics infrastructure provider.

DailyPharm met with Hyun Chul Kim, CEO of Temp Chain Company, to discuss their technical competitiveness, market strategy, and global expansion plans.

A paradigm shift to cold chain…highlights the quality infrastructure, moving beyond logistics

Temp Chain Company develops passive cold chain solutions that minimize temperature deviations during long-distance transport of biopharmaceuticals. Currently, they are targeting the global market with large-scale shipping containers that maintain constant temperatures for long durations without an external power source.

Hyun Chul Kim, CEO of Temp Chain Company

Kim stated, ​"Biopharmaceuticals are extremely sensitive to temperature changes. It is crucial to maintain the quality achieved during production through the logistics stage," and that "Cold chain is no longer viewed as mere logistics equipment; it is now recognized as essential infrastructure that determines the quality of the medicine."

Kim explained that as the proportion of biopharmaceuticals in the market grows, the role of cold chain is evolving. While the focus used to be simply on refrigeration, the industry now demands long-distance transport stability and data-driven quality management.

In particular, Kim emphasized that as global supply chains expand and extreme weather events become more frequent, the transport environment is becoming increasingly complex, underscoring the need for technology that can reliably maintain temperatures over long periods.

​"Bio-logistics must ensure temperature stability across the entire transport process, not just in specific segments," he noted. "Structural design that can maintain temperatures reliably even during long-distance transport is our core competitiveness."

Temp Chain Company is gaining attention for delivering tangible results beyond mere solutions. 

The company has already secured contracts with major domestic pharmaceutical companies. It is expanding collaborations with global pharma giants like Pfizer and Johnson & Johnson, as well as leading logistics providers such as DHL and Expeditors.

These achievements serve as proof that the company has moved beyond the technical validation stage and into commercial application, securing both temperature stability and cost-efficiency in high-volume transport environments.

From materials to finished products…Differentiation through integrated technology

Temp Chain Company's collaborative success is based on its integrated technological competitiveness. 

The performance of a passive cold chain is determined by insulation performance and thermal storage technology. Temp Chain Company has secured both performance and stability by developing and producing Vacuum Insulation Panels (VIP) and Phase Change Materials (PCM) in-house, starting from the material stage.

"The core of cold chain equipment lies in the insulation structure and thermal storage design, yet most companies source these materials externally," Kim stated. "Temp Chain Company has established a system to handle everything internally, from material development and product design to manufacturing and performance verification."

This structure also serves as a strength in terms of R&D speed and price competitiveness. It allows the company to optimize designs based on customer needs and quickly implement improvements. 

Furthermore, the structural design for ensuring temperature stability in long-distance transport environments is cited as a major competitive edge.

Temp Chain Company is building a unique position in the global market through designs specifically specialized for large-scale biopharmaceutical transport. Even when competing against established global leaders, the company is gaining achievements.

​"We focused our development on achieving both large-scale capacity and lightweight design while securing performance and price competitiveness," Kim emphasized. "Solutions that provide efficiency in high-volume transport environments are gaining significant interest in the market."

A transportation device, developed with Temp Chain Company's in-house technology, for passive cold chain solution

Expanding global collaboration…Moving beyond air to ocean

Temp Chain Company is intensifying its market entry by expanding partnerships with global pharmaceutical companies and logistics firms. As biopharmaceutical production and supply become increasingly globalized, demand for long-distance transport is rising sharply, accompanied by a growing need to reduce logistics costs.

​"Pharmaceutical companies are looking for transport methods that can maintain quality while improving logistics efficiency," Kim said. "Interest is growing in passive cold chains that offer large capacity, lightweight features, and low management costs."

A key part of their strategy is expanding from air-centric structures to ocean freight. While ocean transport is highly cost-competitive, it is a field with significant technical barriers due to the difficulty of maintaining temperatures for extended periods.

To address this, the company is advancing its technology by accumulating transport data through R&D.

​"By expanding into ocean freight, we can lower long-distance transport costs while ensuring stability," Kim explained. "Our goal is to build a cold chain solution that can be utilized in multimodal transport environments."

Kim added, "With the expansion of global supply chains, hybrid logistics systems that link various modes of transport will become important," and that "If transport environments involving air, sea, rail, and truck expand, passive cold chain technology, which reduces dependence on electricity, will be ideally suited for such changes."

Aiming to grow into a "Bio-Logistics Infrastructure Company"

Temp Chain Company aims to grow beyond a simple equipment supplier to become a biopharmaceutical logistics infrastructure company.

This goal is based on the judgment that logistics technology is becoming a factor that determines industrial competitiveness alongside the expansion of the biopharmaceutical market.

​"Cold chain is becoming a mandatory infrastructure that must be considered during drug development and commercialization," Kim said. "It will evolve toward ensuring long-distance transport stability and data-based quality management."

As the ocean freight-based business grows, the company has identified 2029 as a major business pivot point. At that stage, they plan to consider an IPO or a strategic investment, depending on corporate value and market conditions.

In the long term, Kim predicts the role of the cold chain will expand amid changes in the global health environment.

​"Technology is needed to supply biopharmaceuticals even in regions lacking reliable refrigeration infrastructure," Kim stated. "Passive cold chain technology can contribute to solving these issues."

In conclusion, Kim added, "Our goal is to create an environment where biopharmaceuticals can be supplied more reliably by establishing global transport solutions that link air and sea. We will continue to expand our presence in the global market based on our technological competitiveness."